Please ensure Javascript is enabled for purposes of website accessibility

Sorrento Therapeutics Stock Could More Than Double, Says Analyst

By Eric Volkman - Jan 30, 2021 at 8:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has several promising treatments in its pipeline.

Sorrento Therapeutics (SRNE 10.00%) is an underappreciated coronavirus stock loaded with potential. So loaded, it's poised to double and then some in value.

That's the opinion of one analyst tracking the stock, Mayank Mamtani of B. Riley Securities. Friday morning, B. Riley initiated coverage of the biotech company, tagging it with a buy rating at a price target of $26 per share.

Sorrento has received considerable attention from investors and biotech industry observers for its efforts to combat the coronavirus. Many are keeping an eye on the company's COVI-MSC experimental stem cell therapy that targets COVID-19, the disease caused by the coronavirus. Encouragingly, on Wednesday Sorrento reported quite positive results from a phase 1b study of COVI-MSC.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

While that's a win for the company (albeit only from limited, early stage testing) Mamtani's enthusiastic recommendation is based not only on its coronavirus efforts. He is also impressed with Sorrento's other products in development, which include therapies covering such disparate uses as non-opioid pain relief and immunotherapy, a very active and promising area of biotech at the moment.

These latter development efforts mean that Sorrento is not a one-trick pony. Even if its coronavirus ambitions fall flat -- and they still might, because after all COVI-MSC was put through its paces in a small, early stage trial -- the company has others to fall back on. This, Mamtani wrote in his research note on the stock, makes it "well positioned for success."

The analyst's bullish take added to recent optimism on Sorrento following those COVI-MSC results. On Friday, the company's stock rose by 3.5%, sharply contrasting with the 1.9% decline of the S&P 500 index.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.43 (10.00%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.